Context Therapeutics Inc. announced its financial results for the year ended December 31, 2024, on March 20, 2025. The company reported cash and cash equivalents of $94.4 million as of December 31, 2024, and expects this to fund operations into 2027.
The year 2024 was described as transformative, marked by strategic acquisitions of CT-95 and the in-licensing of CT-202, expanding the pipeline of T cell-engaging bispecific antibodies. A major milestone for 2025 was achieved with the first patient dosed in the Phase 1 clinical trial of CTIM-76 in January.
Looking ahead, Context anticipates dosing the first patient in its Phase 1 clinical trial of CT-95, targeting mesothelin-expressing cancers, in the second quarter of 2025. The company expects to share initial clinical data from the CTIM-76 Phase 1 trial in the first half of 2026 and from the CT-95 Phase 1 trial in mid-2026. An IND filing for CT-202 is also expected in mid-2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.